Cargando…

Inhibition of metastatic potential in colorectal carcinoma in vivo and in vitro using immunomodulatory drugs (IMiDs)

BACKGROUND: Thalidomide and lenalidomide are FDA approved for the treatment of multiple myeloma and, along with pomalidomide, are being investigated in various other cancers. Although these agents display immunomodulatory, anti-angiogenic and anti-apoptotic effects, little is known about their prima...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, W M, Henry, J Y, Meyer, B, Bartlett, J B, Dalgleish, A G, Galustian, C
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2009
Materias:	Translational Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2736839/ https://www.ncbi.nlm.nih.gov/pubmed/19638977 http://dx.doi.org/10.1038/sj.bjc.6605206

Ejemplares similares

Repurposing Immunomodulatory Imide Drugs (IMiDs) in Neuropsychiatric and Neurodegenerative Disorders
por: Jung, Yoo Jin, et al.
Publicado: (2021)

Recent clinical studies of the immunomodulatory drug (IMiD®) lenalidomide
por: Bartlett, J B, et al.
Publicado: (2005)

IMiDs for myeloma induced renal impairment
por: Gavriatopoulou, Maria, et al.
Publicado: (2018)

IMiD-Free Interval and IMiDs Sequence: Which Strategy Is Better Suited for Lenalidomide-Refractory Myeloma?
por: Suzuki, Kazuhito, et al.
Publicado: (2023)

IMiDs Augment CD3-Bispecific Antibody–Induced CD8(+) T-Cell Cytotoxicity and Expansion by Enhancing IL2 Production
por: Li, Ji, et al.
Publicado: (2023)

A New Generation of IMiDs as Treatments for Neuroinflammatory and Neurodegenerative Disorders
por: Kopp, Katherine O., et al.
Publicado: (2023)

Role of Aiolos and Ikaros in the Antitumor and Immunomodulatory Activity of IMiDs in Multiple Myeloma: Better to Lose Than to Find Them
por: Cippitelli, Marco, et al.
Publicado: (2021)

Immunomodulatory Agents with Antivascular Activity in the Treatment of Non-Small Cell Lung Cancer: Focus on TLR9 Agonists, IMiDs and NGR-TNF
por: Corti, Angelo, et al.
Publicado: (2010)

In vitro and in vivo reversal of resistance to 5-fluorouracil in colorectal cancer cells with a novel stealth double-liposomal formulation
por: Fanciullino, R, et al.
Publicado: (2007)

Pathological responses after angiogenesis or EGFR inhibitors in metastatic colorectal cancer depend on the chemotherapy backbone
por: Carrasco, J, et al.
Publicado: (2015)

Internal ribosome entry site of bFGF is the target of thalidomide for IMiDs development in multiple myeloma
por: Lien, I-Chia, et al.
Publicado: (2014)

Attenuation of muscle atrophy in a murine model of cachexia by inhibition of the dsRNA-dependent protein kinase
por: Eley, H L, et al.
Publicado: (2007)

Synthetic phosphoethanolamine has in vitro and in vivo anti-leukemia effects
por: Ferreira, A K, et al.
Publicado: (2013)

Telomere length is a novel predictive biomarker of sensitivity to anti-EGFR therapy in metastatic colorectal cancer
por: Augustine, T A, et al.
Publicado: (2015)

Drug-induced senescence bystander proliferation in prostate cancer cells in vitro and in vivo
por: Ewald, J A, et al.
Publicado: (2008)

Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer
por: Marmorino, Federica, et al.
Publicado: (2017)

IMiDs induce FAM83F degradation via an interaction with CK1α to attenuate Wnt signalling
por: Dunbar, Karen, et al.
Publicado: (2020)

Early endostatin treatment inhibits metastatic seeding of murine colorectal cancer cells in the liver and their adhesion to endothelial cells
por: te Velde, E A, et al.
Publicado: (2005)

Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer
por: Codony-Servat, Jordi, et al.
Publicado: (2017)

Trastuzumab induced in vivo tissue remodelling associated in vitro with inhibition of the active forms of AKT and PTEN and RhoB induction in an ovarian carcinoma model
por: Delord, J-P, et al.
Publicado: (2010)

Prognostic and predictive value of TOPK stratified by KRAS and BRAF gene alterations in sporadic, hereditary and metastatic colorectal cancer patients
por: Zlobec, I, et al.
Publicado: (2010)

Texture analysis of (125)I-A5B7 anti-CEA antibody SPECT differentiates metastatic colorectal cancer model phenotypes and anti-vascular therapy response
por: Rajkumar, V, et al.
Publicado: (2015)

Synergistic anti-cancer effects of immunotoxin and cyclosporin in vitro and in vivo
por: Andersson, Y, et al.
Publicado: (2009)

Directing HER4 mRNA expression towards the CYT2 isoform by antisense oligonucleotide decreases growth of breast cancer cells in vitro and in vivo
por: Nielsen, T O, et al.
Publicado: (2013)

Effective treatment of chemoresistant breast cancer in vitro and in vivo by a factor VII-targeted photodynamic therapy
por: Duanmu, J, et al.
Publicado: (2011)

Underexpression of tumour suppressor LKB1 in clear cell renal cell carcinoma is common and confers growth advantage in vitro and in vivo
por: Duivenvoorden, W C, et al.
Publicado: (2013)

In vitro and in vivo multidrug resistance reversal activity by a Betti-base derivative of tylosin
por: Gyémánt, N, et al.
Publicado: (2010)

Mitogen-activated protein kinase phosphatase-1 (MKP-1) impairs the response to anti-epidermal growth factor receptor (EGFR) antibody cetuximab in metastatic colorectal cancer patients
por: Montagut, C, et al.
Publicado: (2010)

In vivo and in vitro properties of STX2484: a novel non-steroidal anti-cancer compound active in taxane-resistant breast cancer
por: Stengel, C, et al.
Publicado: (2014)

Upregulation of ERCC1 and DPD expressions after oxaliplatin-based first-line chemotherapy for metastatic colorectal cancer
por: Baba, H, et al.
Publicado: (2012)

Inhibition of hyaluronan retention by 4-methylumbelliferone suppresses osteosarcoma cells in vitro and lung metastasis in vivo
por: Arai, E, et al.
Publicado: (2011)

In vitro hypoxia-conditioned colon cancer cell lines derived from HCT116 and HT29 exhibit altered apoptosis susceptibility and a more angiogenic profile in vivo
por: Yao, K, et al.
Publicado: (2005)

In vitro and in vivo anticancer effects of mevalonate pathway modulation on human cancer cells
por: Jiang, P, et al.
Publicado: (2014)

Molecular targeting of retinoic acid metabolism in neuroblastoma: the role of the CYP26 inhibitor R116010 in vitro and in vivo
por: Armstrong, J L, et al.
Publicado: (2007)

Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo
por: Lamont, F R, et al.
Publicado: (2011)

Prognostic role of ERBB2, MET and VEGFA expression in metastatic colorectal cancer patients treated with anti-EGFR antibodies
por: Takahashi, Naoki, et al.
Publicado: (2016)

Combined PI3K and CDK2 inhibition induces cell death and enhances in vivo antitumour activity in colorectal cancer
por: Beale, Gary, et al.
Publicado: (2016)

Antitumour activity of XR5944 in vitro and in vivo in combination with 5-fluorouracil and irinotecan in colon cancer cell lines
por: Harris, S M, et al.
Publicado: (2005)

BCRP expression does not result in resistance to STX140 in vivo, despite the increased expression of BCRP in A2780 cells in vitro after long-term STX140 exposure
por: Day, J M, et al.
Publicado: (2009)

Telomere uncapping by the G-quadruplex ligand RHPS4 inhibits clonogenic tumour cell growth in vitro and in vivo consistent with a cancer stem cell targeting mechanism
por: Phatak, P, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_o7rdn34j2offol49knl4qnjecb